NSW2031 - Randwick - Sydney Children's Hospital (SUSPENDED)2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)2305 - New Lambton Heights - John Hunter Children's Hospital (SUSPENDED)

QLD4101 - South Brisbane - Queensland Children's Hospital (SUSPENDED)

WA6009 - Perth - Perth Children's Hospital (SUSPENDED)

NCT04322318

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) (AREN1921)

NSW2031 - Randwick - Sydney Children's Hospital (SUSPENDED)2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)2305 - New Lambton Heights - John Hunter Children's Hospital (SUSPENDED)

3168 - Clayton - Monash Medical Centre (SUSPENDED)

SA5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (SUSPENDED)

NCT04293562

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations (AAML1831)

QLD4101 - South Brisbane - Queensland Children's Hospital (SUSPENDED)

NCT04221035

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)

2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)

WA6009 - Perth - Perth Children's Hospital (SUSPENDED)

NCT04094610

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE) (CA127-1029)

2145 - Westmead - The Children's Hospital at Westmead (COMPLETED)

NCT03959085

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (AALL1732)

2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)

NCT03838042

INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt) (Final4,-18-10-2023)

NCT03394365

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)

QLD4032 - Chermside - The Prince Charles Hospital (COMPLETED)

NCT02840409

A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Na�ve Children With Unresectable or Progressive Low Grade Glioma (LGG)

Filters

Recruitment Status

Recruitment Country and State

Phase

Trial Type

Cancer Therapy Class

CD19	19%
PD-1	14%
PD-1/PD-L1	14%
KIT	10%
PDGFR	10%
VEGFR	10%
CD20	10%
CD123	5%
proteasome	5%
BCR-ABL1	5%
PDGFRA	5%
SCFR	5%
LAG3	5%
PI3K	5%
PI3K delta	5%
PI3Kalpha	5%
mTOR	5%
mTORC1	5%
mTORC2	5%
BRAF	5%
CRAF	5%
RAF	5%
FGFR	5%
FGFR1	5%
FGFR1/2/3	5%
FGFR2	5%
FGFR3	5%
FGFR4	5%
RET	5%
AXL	5%
CD33	5%
FLT3	5%
GD2	5%
ALK	5%
ROS1	5%
TRK	5%
CD22	5%
HDAC	5%
EBV	5%
VEGF	5%

Facility

Cancer Type

ARTICANZ - Beta (ver 0.91)

Search results

Filters